ArticleDermatology and therapyPublished
Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial
Regional connection
Verified An author affiliation on the Europe PMC record names Bristol Myers Squibb. Affiliation source
- Institution
- Bristol Myers Squibb
- County
- Mercer County
Publication record
- Type
- Article
- Venue
- Dermatology and therapy
- Published
- Topic
- Clinical care
- Subject terms
- Cytokine; Pharmacodynamics; Psoriasis; Tyrosine Kinase 2; Deucravacitinib
- PubMed ID
- 39283417
- PubMed Central ID
- PMC11480296
- Open access
- Yes, open
- Added to directory
- Source checked